Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.00542560478538342 | N/A |
Market Cap | $7.31M | N/A |
Shares Outstanding | 1.35B | 51.92% |
Employees | 0 | N/A |
Shareholder Equity | 3.76M | -6.76% |
Valuation | 2023 | Change |
---|---|---|
P/B Ratio | 1.94 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.3800 | N/A |
Earnings | 2023 | Change |
---|---|---|
Earnings | -$1.43M | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $2.86M | N/A |
Cash on Hand | $2.79M | N/A |
Debt to Equity | 0.0811 | 101.65% |
Current Ratio | $9.35 | -47.58% |